Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial,The Lancet Respiratory Medicine

当前位置： X-MOL 学术 › Lancet Respir. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2024-09-09 , DOI: 10.1016/s2213-2600(24)00178-4
Baohui Han ₁ , Trevor Feinstein ₂ , Yuankai Shi ₃ , Gongyan Chen ₄ , Yu Yao ₅ , Chunhong Hu ₆ , Jianhua Shi ₇ , Jifeng Feng ₈ , Huijuan Wu ₉ , Ying Cheng ₁₀ , Qi-Sen Guo ₁₁ , Zhijun Jie ₁₂ , Feng Ye ₁₃ , Yiping Zhang ₁₄ , Zhihua Liu ₁₅ , Weidong Mao ₁₆ , Liangming Zhang ₁₇ , Junguo Lu ₁₈ , Jun Zhao ₁₉ , Lyudmila Bazhenova ₂₀ , Jimmy Ruiz ₂₁ , Goetz H Kloecker ₂₂ , Kalmadi R Sujith ₂₃ , Ira A Oliff ₂₄ , Matthew Wong ₂₅ , Bin Liu ₂₆ , Yanping Wu ₂₆ , Lan Huang ₂₆ , Yan Sun ₃ ,

Affiliation

Shanghai Chest Hospital, Respiratory Medicine Department, Shanghai Jiao Tong University, Shanghai, China.
Piedmont Cancer Institute, Atlanta, GA, USA.
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Medical Oncology, Beijing, China.
Harbin Medical University Cancer Hospital, Medical Oncology, Harbin, Heilongjiang Province, China.
The First Affiliated Hospital of Xi'an Jiaotong University, Medical Oncology, Xi'an, Shanxi Province, China.
The Second Xiangya Hospital of Central South University, Oncology Department, Changsha, Hunan Province, China.
Linyi Cancer Hospital, Medical Oncology, Linyi, Shandong Province, China.
Jiangsu Cancer Hospital, Medical Oncology, Nanjing, Jiangsu Province, China.
Henan Cancer Hospital, Medical Oncology, Zhengzhou, Henan Province, China.
Jilin Cancer Hospital, Thoracic Medical Oncology, Changchun, Jilin Province, China.
Shandong Cancer Hospital, Medical Oncology, Jinan, Shandong Province, China.
Shanghai Fifth People's Hospital, Medical Oncology, Fudan University, Shanghai, China.
The First Affiliated Hospital of Xiamen University, Medical Oncology, Xiamen, Fujian Province, China.
Zhejiang Cancer Hospital, Medical Oncology, Hangzhou, Zhejiang Province, China.
Jiangxi Cancer Hospital, Medical Oncology, Nanchang, Jiangxi Province, China.
Jiangyin People's Hospital, Medical Oncology, Jiangyin, Jiangsu Province, China.
Yantai Yuhuangding Hospital, Medical Oncology, Yantai, Shandong Province, China.
Nantong Tumor Hospital, Medical Oncology, Nantong, Jiangsu Province, China.
Beijing Cancer Hospital, Medical Oncology, Beijing, China.
University of California San Diego, Moores Cancer Center, San Diego, CA, USA.
Wake Forest University Health Systems, Hematology and Oncology, W.G. (Bill) Hefner Veterans Affairs Medical Center, Salisbury, NC, USA.
University of Louisville Hospital, Louisville, KY, USA.
Ironwood Cancer and Research Centers, Chandler, AZ, USA.
Orchard Healthcare Research, Skokie, IL, USA.
Central Coast Cancer Centre, Gosford Hospital, Gosford, NSW, Australia.
BeyondSpring Pharmaceuticals, Florham Park, NJ, USA.

There is an unmet need for second-line and third-line treatments that are effective and tolerable for advanced or metastatic non-small-cell lung cancer (NSCLC) with no driver mutations.

中文翻译：